Nick is a Clinical Reader and consultant in Gastroenterology. His key clinical and research interests focus on intestinal inflammation in the context of inflammatory bowel diseases (such as ulcerative colitis and Crohn’s disease), but also in gut inflammation resulting from certain treatments, such as immune checkpoint inhibitors.
His research group focuses on the molecular and cellular mechanisms responsible for mediating chronic intestinal inflammation, and understanding the dialogue between intestinal microbes and host immunity. His lab is also interested in understanding how cell-specific and tissue-specific transcriptional programmes, including cytokine-responsive networks, disclose important information about disease pathogenesis, and how these "molecular signatures" can be harnessed to predict patient outcomes.
He was previously awarded a Wellcome Trust Intermediate Clinical Fellowship (2013-2019). He completed specialist registrar training in gastroenterology and internal medicine in London (Hammersmith, St Mary’s). He has also been awarded an MSc (Imperial College London) and PhD in immunology (King’s College London). Major funding has been awarded by the Wellcome Trust, MRC and Crohn’s and Colitis UK. Some key publications include; Powell N, et al. Gastroenterology (2015); 149:456-467, Goldberg R, et al. Nature Reviews in Gastroenterology and Hepatology (2015); 12:271-283, Powell N, et al. Immunity (2012); 37:674-84.
et al., 2022, Oral Beclomethasone Dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis, Journal for Immunotherapy of Cancer, ISSN:2051-1426
et al., 2022, Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy, Nature Communications, ISSN:2041-1723
et al., 2022, COVID-19 vaccine-induced antibody and T cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose: a multicentre, prospective, case-control study, The Lancet Gastroenterology & Hepatology, ISSN:2468-1253
et al., 2022, Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic, Gut, ISSN:0017-5749
et al., 2022, SARS-CoV-2 vaccination for patients with inflammatory bowel disease – Authors' reply, The Lancet Gastroenterology and Hepatology, Vol:6, ISSN:2468-1253, Pages:523-524